Medidata Solutions
, a global provider of SaaS-based clinical development solutions, announced that Australian contract research organization (CRO) Novotech has joined Medidata’s
ASPire to Win
® channel partner program. As the largest full-service Australian CRO, Novotech can now offer sponsors a full range of services around the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) solution. Novotech plans to leverage Medidata Rave to streamline the clinical research process for customers conducting Phase I-III trials in nine countries and across a range of therapeutic categories.
Headquartered in Sydney, Novotech works with biotechnology and pharmaceutical companies in North America and Europe to bring new products to the global market by offering a full range of ICH-compliant clinical services, from first human exposure through to completion of Phase III trials. As the demand for global clinical outsourcing services continues to grow, Novotech selected Medidata Rave and joined the ASP
ire
to Win program for Medidata’s ability to handle large, complex, global studies and its comprehensive partner enablement program.
“Medidata Rave is a robust system with global capabilities, a clear, intuitive interface and widespread acceptance among our global sites,” said Alek Safarian, CEO, Novotech. “Medidata also offers the technology and support that allows us to improve communication and streamline data collection and management with many of our clients based in North America and Europe, enabling us to drive global reach and close the distance gap.”
Novotech is now pursuing Rave Accredited Plus, the most advanced level in Medidata’s channel partner program. Once at this level, Novotech will be positioned to provide the full range of Rave-related services, including end-user training, study build, reporting, outputs, integrations and migrations.
“We are very excited to add Novotech as the first Australian-based CRO in our ASP
ire
to Win program,” said Graham Bunn, Vice President for Global CRO Partnerships, Medidata Solutions. “Our experience in helping sponsors and CROs facilitate clinical trials on a global scale makes us a natural partner to support Novotech’s clinical support goals, and we look forward to helping drive their future research initiatives.”
Medidata first announced ASP
ire
to Win in April 2005 as a channel partner program designed to enable select CROs and other service providers to offer Medidata Rave implementation services. Since then, ASP
ire
to Win has grown to include more than 25 partners.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.